For the quarter ending 2025-12-31, INM made $820,188 in revenue. -$2,028,223 in net income. Net profit margin of -247.29%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Sales | 820,188 | 1,120,121 | 1,225,998.333 | - |
| Cost of sales | 635,994 | 716,962 | 1,023,802.833 | - |
| Gross profit | 184,194 | 403,159 | 606,586.5 | 0 |
| Research and development | 630,636 | 581,612 | 694,246.667 | - |
| General and administrative | 1,621,095 | 1,532,015 | 1,711,965.333 | - |
| Amortization and depreciation | 53,201 | 53,202 | 52,753.333 | - |
| Foreign exchange loss (gain) | 18,136 | -56,994 | 1,239,137.667 | - |
| Total operating expenses | 2,286,796 | 2,223,823 | 3,712,338.5 | 0 |
| Interest and other income | 74,379 | 93,765 | 32,929.333 | - |
| Finance expense | - | - | 92,887.25 | - |
| Loss before income taxes | -2,028,223 | -1,726,899 | -3,242,132.5 | 0 |
| Net loss for the period | -2,028,223 | -1,726,899 | -2,161,421.667 | - |
| Basic (in dollars per share) | -0.51 | -0.44 | -1.855 | -1.94 |
| Basic (in shares) | 3,954,549 | 3,954,549 | -370,057.5 | 1,095,973 |
| Diluted (in dollars per share) | -0.51 | -0.44 | -1.855 | -1.94 |
| Diluted (in shares) | 3,954,549 | 3,954,549 | -370,057.5 | 1,095,973 |
InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc. (INM)